cooper finish fiscal strong increas fve due
favor outlook len market
page full analyst note dec
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim aug
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
cash-pay busi sticki custom competitor
contact len industri attract market opinion
valeant control approxim global market
industri regul creat strong barrier entri keep new
entrant away remain pure-play contact len
manufactur fell behind peer earli
competitor brought silicon hydrogel lens market
launch full portfolio lens regain lost
share larg detriment novarti alcon busi
even though concern increas competit
specialti len market benefit new higher-pr
product offer silicon hydrogel one-day premium
lens addit expir royalti payment expect
expand margin maintain double-digit earn
believ cooper sale growth driven two key factor
first see increas adopt contact lens world-wide
larg emerg market unpreced rise myopia
particularli under-penetrated asian market present
long-term growth opportun histor adopt rate
second believ exist custom trade premium
product daili dispos lens grow popular across
globe expans myday brand daili
dispos silicon hydrogel lens plu acquir clariti brand
give firm two new lens segment daili lens
conveni custom reduc risk infect
silicon hydrogel lens provid comfort len wearer
compar tradit hydrogel
expand portfolio well-posit benefit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
cooper compani oper two unit coopervis coopersurg
account total sale coopervis one world
top four develop manufactur contact lens
coopervis sale intern territori second unit
coopersurg develop manufactur diagnost surgic
product gynecologist obstetrician
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
favor outlook len market dec
report solid fourth-quart result revenu
last year million bring full-
year revenu billion increas last
year constant currenc trade-up trend daili
silicon hydrogel show sign slow
firm share daili market still under-penetrated
indic room grow global addit
paragard perform well driven sustain margin
improv surgic effect slightli
off-set increas sale market spend cooper
continu hire sale rep invest asia-pacif
region capit expenditur larg due expand
manufactur line steadi uptak daili lens
like rais fair valu estim revisit
long-term assumpt segment
maintain narrow moat due strong
len portfolio continu pick share global
expect fiscal sit higher end
manag new guidanc billion vision
revenu million surgic revenu
cooper vision toric lens daili continu drive
growth last year constant
currenc respect toric daili also drove
growth america revenu healthi
follow launch myday toric earlier year
asia-pacif region continu post double-digit
increas contribut firm revenu
call manag express confid
continu see double-digit increas asia
fourth quarter top line healthi cooper
vision gross margin came lower anticip
compar adjust basi last year
declin mostli currenc headwind
also affect higher ship distribut
cost write-off legaci hydrogel lens expect
pressur distribut cost continu
near term focus deliv high-qual
servic premier ship especi len
subscript program gain traction expect
inventori write-off result better-than-expect uptak
silicon hydrogel impact fiscal
cooper surgic contribut million
one fourth firm total revenu led
paragard offset weak fertil
genom busi paragard boost segment
fourth-quart gross margin compar
adjust basi last year offic surgic product
outsid paragard perform well increas
manag attribut quarter paragard
growth channel inventori expans firm focus
market campaign pay firm hire new sale
rep paragard bring salesforc
product post strong growth fiscal
note also invest heavili sale
market effort expect continu
maintain fair valu estim per
share impli forward price/adjust earn
multipl
expect on-going adopt silicon
hydrogel product combin custom upgrad
daili dispos lens drive firm five-year
compound annual growth rate expect market
share gain margin expans continu consum
upgrad newer lens biofin energi
control frequent replac space
daili contact len space forecast modest
market share gain consum base move
higher-margin lens believ margin expans
drive even faster earn growth manufactur yield
improv custom continu switch higher-pr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
scenario assum oper margin
expand daili lens carri high gross profit
dollar term compar modal margin
seem like improv growth rate daili silicon
hydrogel lens higher expect surgic
busi also seem like accret gross margin
start contribut larger proport sale
assumpt arriv fair valu estim
bear case assum sale growth slow
five-year compound-annual-growth-rate oper margin
result fair valu estim could
occur stumbl incorpor anoth
acquisit face greater-than-expect declin
surgic lens-car busi due competit
believ central player oligopolist
contact len industri narrow moat due intang
asset cost advantag scale hold
roughli share global contact len market
surpass novarti alcon johnson
johnson along valeant bausch lomb
compani make global contact len
market coopervis shield barrier entri
vision-car market allow firm produc consist
econom profit expect materi chang
contact len adopt overal given inconveni
eyeglass complic expens associ
coopervis contribut overal sale
fiscal leader multifoc toric contact
lens specialti lens
compani sale requir complex manufactur
fit process sold premium price spheric
lens johnson johnson came toric
manufactur effici contact lens expand
oper margin
aim second-largest len compani
market share world-wide next two year
believ track achiev goal current
underindex asia nearli two third sale
region stem japan alon expect
build market share high adopt rate region
continu weigh threat competitor
johnson johnson aggress
move toric multifoc space recent year
cash-pay natur contact len market support
medium uncertainti rate
bullish scenario assum greater proport
sale firm myday clariti daili contact lens
market share gain len segment steadi growth
surgic segment increas five-year compound-annual-growth-rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
daili silicon hydrogel lens
contact len maker offer toric multifoc varieti
daili dispos silicon hydrogel lens allow
gain modest share specialti len space make
late entri silicon hydrogel gain
share past sever year silicon hydrogel lens
prolifer thank broad portfolio spheric
toric multifoc lens across three modal
face addit upsid contact len wearer upgrad
lens
regul natur contact len industri fortifi
coopervis competit posit intang
asset first lens must approv regul
 food drug administr typic
patent protect exampl coopervis one
mani patent aquaform technolog techniqu use
biofin monthli avaira biweekli famili
aquaform high oxygen transmiss low
modulu keep len softer flexibl
competitor second research develop
spend allow firm invest new technolog
bring new lens market third current law
patient must visit licens optometrist purchas
contact lens must get prescript fill everi time
need order new suppli prescript
brand-specif requir new entrant build
level trust medic commun doctor
hesit embrac new product
proven record safeti often receiv rebat
manufactur necessari doctor visit lead doctor
recommend establish brand bolster
coopervis competit posit contact len
addit custom content certain brand
lens unlik switch manufactur
typic strong
custom comfort product unlik
chang lens minor improv small reduct
price contact lens typic come
suppli discourag frequent brand-switch
relationship
manufactur like chang brand len
prescrib given custom contact lens
larg paid pocket coopervis larg
unaffect pressur insur seen ration
price prevail past decad expect
price war emerg
moreov manufactur contact lens capital-intens
complic process creat cost advantag
top four len manufactur cooper manufactur
knowledg continu expand evidenc improv
gross margin better factori util new entrant
would need invest signific time fix cost
suffici qualiti meet regulatori requir new
product typic sold loss first coupl
year manufactur reach necessari scale bring
cost per unit due sticki custom base
space new competitor would unlik win
enough new patient ever reach critic mass need
oper profit given up-front cost
difficulti captur new custom exist brand
anticip new entrant space
believ coopersurg overal sale
fiscal produc medic devic relat
women health contribut econom moat
due numer establish competitor johnson
 johnson coopersurg revenu
grew compound annual rate last three
year larg driven heavi
activ includ firm recent billion acquisit
teva paragard
iud although manag
expand segment portfolio recent year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
yet view moatworthi busi think
coopersurg coopervis benefit cost
synergi given busi dispar natur
believ stabl moat trend sinc launch
silicon hydrogel len portfolio maintain
gain market share categori lens still
expect materi chang competit dynam
among
manufactur also think barrier entri
substanti enough preclud new competitor
enter market custom unlik switch
brand contact lens expand portfolio
len modal specialti lens help gain
market share rel alcon bausch lomb novarti
recent express interest spin alcon
busi valeant balloon debt
uncertainti ophthalmolog segment bausch
lomb develop bode well coopervis
control lion share industri give firm
price power peer
think coopersurg competit posit
materi chang either although firm invest
widen surgic segment ivf fertil portfolio
competit women health among devic maker
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ocoopervis benefit custom trade
weekli monthli contact lens expens
oover revenu come foreign
currenc leav compani suscept
chang exchang rate
major contact len manufactur
offer valu daili silicon hydrogel option addit
lens normal price point help
ofollow complet sauflon acquisit
expir royalti payment ciba vision
oper margin continu improv
oper leverag product mix
laggard bring silicon hydrogel
lens market indic
ocoop competitor larger divers
revenu stream allow greater research
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
work pay debt past year
firm debt/ebitda fiscal
end fiscal firm took billion
debt fiscal financ acquisit teva
paragard iud even addit leverag
anticip challeng meet
oblig given sticki custom minim econom
sensit contact len market alreadi extrem
consolid especi sauflon acquisit
futur larg acquisit seem unlik coopervis
firm may seek addit capit pursu bolt-on
deal surgic divis coopersurg acquir
compani sinc project
histor innov leader
firm late game silicon hydrogel product
risk behind curv futur
innov howev briskli regain market
share later come one complet
suit silicon hydrogel product capit
weak alcon bausch lomb opinion
abil quickli regain lost ground highlight
stabil industri establish player also
face product recal risk issu recal avaira line
lens minor issu recal
appear caus sustain damag
firm brand seriou recal potenti damag
reput ultim reduc earn addit
investor awar risk associ
devast impact hurrican maria puerto rico late
septemb coopervis global manufactur
capabl primari three facil locat
puerto rico hungari unit kingdom puerto
rican facil employe local worker
sustain minor damag util gener
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
maintain power compani comment product
continu facil shipment leav
island difficult evalu extent product
issu potenti cost result hurrican
facil manufactur
coopervis product volum larg focus
high-margin silicon hydrogel lens key driver
earn growth busi estim
six month inventori distribut center
 belgium
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
manag behind innov curv vision
care invest enough research develop
silicon hydrogel lens howev coopervis sinc
regain lost ground quickli adapt market trend
focus specialti lens addit believ
manag kept sound merger acquisit
polici segment opinion done
commend job recent year build portfolio
product expand global market share
repres date owner name posit common share held report holder issuer
share
fund
share
fund
past manag larg use excess capit
bolt-on acquisit except
acquisit sauflon billion recent
billion acquisit paragard believ benefit
sauflon deal outweigh associ expens
oper difficulti firm face year
follow acquisit firm use acquisit
support moat vision care enter
mass-market hydrogel space financ paragard
acquisit ad billion debt balanc
sheet also ad steadi high-margin busi
expand surgic divis product portfolio
believ manag respons run two
dispar segment coopervis coopersurg
alloc cash flow new opportun come
industri acquisit paragard iud
exampl strategi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
coopersurg result fell line expect
post growth constant currenc driven
growth paragard gross margin improv basi
point last year thank paragard
firm previous announc continu increas
sale market effort captur paragard recent
momentum off-set weak
gener paragard allow firm
significantli pay debt quarter borrow
billion acquisit addit pay
debt expect firm continu use cash
small acquisit surgic segment
increasingli focus fertil
cooper post solid growth vision surgic
cooper compani execut well third quarter
strong growth vision surgic segment
manag updat fiscal guidanc account
excess tax benefit expect materi
chang fair valu estim per share line
expect coopervis revenu increas
last year constant currenc coopersurg
revenu compani continu
realiz higher gross margin paragard mix shift
higher-margin lens trade-up trend boost
contact len industri post high- mid-single-digit
growth compar histor rate
believ strength across complet portfolio
lens highlight firm narrow econom moat
help firm win market share
coopervis growth bolster revenu
silicon hydrogel daili constant
currenc favor product mix improv gross margin
basi point slightli off-set increas rebat
activ multifoc grew constant currenc
toric lens track lower expect growth
geograph revenu trend
line
expect america constant currenc
show continu improv addit emea
asia firm report capac constraint
third quarter demand biofin monthli
lens higher expect call manag
assur sinc ad capac note even
small execut misstep hinder
compet larger effici competitor accordingli
pleas hear increas invest distribut
center market key account addit
dedic research develop next gener
product believ necessari step fortifi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end octob
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end octob
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
